Abhishek Bhattacharjee

Su1855: NET REMISSION RATES WITH ADVANCED THERAPIES IN ULCERATIVE COLITIS: AN ANALYSIS OF PHASE 3 RANDOMIZED CONTROLLED TRIALS

Maia Kayal, Marla Dubinsky, Ryan C. Ungaro, Carlos Stalgis et autres

Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis—A Safety Analysis

Anita Afzali, Miguel D. Regueiro, Andres J. Yarur, Yamile Zabana et autres

BACKGROUND: receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the S1P receptor modulator ozanimod, etrasimod does not have a molecular structure to inhibit monoamine oxidase (MAO). Coadministration of drugs that inhibit MAO with opioids and antidepressants …

us, es, hk, gb, ch, in, fr (code pays fourni par la source)

Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials

Elena Sonnenberg, Charlie W. Lees, Filip Baert, Christina Piperni et autres

Introduction: Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P) 1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Objectives: We assessed etrasimod efficacy and safety in biologic/Janus kinase inhibitor (JAKi)-naïve patients (pts) who previously took 5-aminosalicylic …

de, gb, be, ca, us, in, fr (code pays fourni par la source)

P795 Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: Data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials

Elena Sonnenberg, Charlie W. Lees, Filip Baert, Christina Piperni et autres

Abstract Background Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). We present data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials1 assessing etrasimod …

de, gb, be, ca, us, in, fr (code pays fourni par la source)

P524 Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis

Anita Afzali, Miguel D. Regueiro, Andres J. Yarur, Yamile Zabana et autres

Abstract Background Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis (UC). Unlike the other S1P receptor modulator approved for UC, etrasimod and its metabolites do not have a …

us, es, hk, gb, ch, in, fr, ca (code pays fourni par la source)

Another look at binocular vision: Contribution to online control processes.

Damian M. Manzone, Abhishek Bhattacharjee, John de Grosbois, Gerome Aleandro Manson et autres

Ample research has investigated the advantage of binocular over monocular vision. In this study, we aimed to better understand the use of monocular vs. binocular visual feedback for the control of on-going upper-limb reaching movements. If binocular cues (e.g., binocular disparity) contribute …

ca (code pays fourni par la source)